Navi Medical Technologies has raised A$6.8 million to commercialize its Neonav vascular access technology in the United States following FDA clearance and the beginning of clinical evaluations at two major U.S. children’s hospitals. Commercial sales are expected to begin during 2026.
The financing was led by healthcare venture capital firm KP Rx, which invested A$4 million. Existing investor Innovation Victoria and Pacific Channel also participated. Navi plans to use the capital to expand manufacturing, establish a U.S. commercial team and introduce Neonav at leading pediatric hospitals.
Neonav is designed to help clinicians position and monitor central venous access devices used to deliver fluids, nutrition and medication to neonatal and pediatric patients. Accurate placement is particularly important because a catheter positioned incorrectly or displaced after insertion can damage the heart or surrounding tissue and may produce severe complications.
Adult clinicians commonly use electrocardiogram-guided catheter placement, but pediatric teams continue to rely heavily on X-ray confirmation because existing systems were not designed around the anatomy and clinical requirements of very small patients. Neonav uses real-time intravascular ECG signals to support catheter tip placement and ongoing surveillance for migration.
The ability to reassess catheter location after insertion distinguishes the system from conventional tip-location technologies. Ongoing monitoring may allow clinicians to identify movement without relying exclusively on repeated imaging, potentially improving safety while reducing the use of additional X-rays.
Neonav received FDA 510(k) clearance in 2025. An expanded indication granted in 2026 added applications involving umbilical venous catheters, giving the platform cleared uses across central venous access devices and procedures for neonatal and pediatric patients.
KEY QUOTES:
“Neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients.”
Alex Newton, Chief Executive Officer of Navi Medical Technologies
“Navi has developed a genuinely differentiated technology addressing a significant unmet clinical need. The company has demonstrated exceptional execution, from product development to FDA clearance and early engagement with leading U.S. children’s hospitals.”
“We believe the Neonav has the potential to become an important new technology in neonatal and paediatric vascular access, and we’re excited to support the team as they scale.”
Hashan De Silva, Partner at KP Rx
“For decades, neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients. The Neonav was built to change that.”
“This investment allows us to scale manufacturing, grow our U.S. team and partner with leading children’s hospitals as we work to establish a new standard of care in neonatal and paediatric vascular access.”
Alex Newton, Chief Executive Officer of Navi Medical Technologies
“What stands out about Navi is the quality of both the innovation and the execution. The team has consistently delivered on major milestones and demonstrated that a Victorian company can develop world-leading healthcare technology with global relevance.”
“Their progress over the past year has been exceptional, and we’re pleased to continue supporting their growth as they take this technology to more hospitals and more patients around the world.”
Rod Bristow, CEO of Innovation Victoria
“Navi has developed a highly differentiated technology that addresses a significant unmet need in neonatal and paediatric critical care.”
“The team has impressively navigated a demanding clinical and regulatory pathway, achieving important milestones that position the company strongly for future growth and reinforce its potential to establish itself as a global leader in this category.”
“We’re excited to support Navi as it enters the next stage of commercial growth in the United States.”
Roland Toder, General Partner at Pacific Channel
